Dr. Alok K. Mishra is a biotechnology expert specializing in immune-oncology and cancer drug discovery. He earned his Ph.D. in Biological Sciences from Central Drug Research Institute, India, studying mycobacterial genetics and immuno-biology. He completed his postdoctoral training in the laboratory of renowned cancer biologist Dr. Michael R. Green at the University of Massachusetts Chan Medical School, USA, where he investigated regulatory networks of innate immune checkpoints and oncogenic drivers in cancer. Currently, Dr. Mishra is a Research Scientist in the Department of Hematopoietic Biology and Malignancy at MD Anderson Cancer Center, USA, focusing on tumor–immune cell interactions and the development of targeted and cellular immunotherapies for solid malignancies. His research has led to the filing of two international patents on formulating novel ovarian cancer treatments and selective targeting of cancer stem cells in glioblastoma. Dr. Mishra has also published in high-impact journals and serves as a peer reviewer and associate editor for leading biomedical Journals. As a corresponding editor of this book, he brings scientific expertise and a commitment to innovation, curating cutting-edge content that addresses key challenges in cancer biology and immunotherapy. His work holds significant translational potential, aiming to improve cancer patient outcomes and advance cancer immunotherapies.
Dr. Sunil K. Malonia is an accomplished cancer biologist and an instructor/faculty member in the Department of Molecular, Cell, and Cancer Biology at UMass Chan Medical School, USA. He earned his PhD in Biotechnology from the National Center for Cell Science in India, where his research focused on the precise regulation of gene expression by cis-regulatory DNA elements in cancer. He completed his postdoctoral research at the Howard Hughes Medical Institute, University of Massachusetts Medical School, where he investigated the epigenetic regulation of tumor suppressor genes and oncogenes in various cancers. Dr. Malonia’s current research program focuses on identifying therapeutically targetable pathways in cancer, with a particular emphasis on understanding the molecular mechanisms of cancer progression, chemoresistance,
and immune evasion. Some of his work has led to the identification of novel drug targets in cancer and the development of promising therapeutic strategies. An active contributor to the scientific community, Dr. Malonia has authored numerous research publications and review articles and serves as a peer reviewer for multiple scientific journals. As the senior editor of this book, he brings a unique blend of scientific expertise and translational insight, particularly in immuno-oncology and immunotherapy. His leadership and editorial contributions reflect his steadfast commitment to advancing cancer research and fostering innovative immune therapeutic approaches.